SCHEMBL26102750

SCHEMBL26102750

CC1(F)CCN(C(=O)c2ccc(C#N)cc2Br)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP1A2 P05177 1/20 0.39
MAPK1 P28482 1/20 0.39
CCKBR P32239 1/20 0.39
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
EPHX2 P34913 1/20 0.38
CYP2C19 P33261 1/20 0.38
FASN P49327 8/20 0.38
SLC6A9 P48067 2/20 0.38
SLC6A5 Q9Y345 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP3A4 P08684 1/20 0.38
MBTD1 Q05BQ5 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23981666 0.90 SLC6A9 (0.40) USP2SMN1; SMN2CYP1A2MAPK1CCKBR
SCHEMBL30396674 0.90 SLC6A9 (0.40) USP2SMN1; SMN2CYP1A2MAPK1CCKBR
SCHEMBL23981996 0.86 SMN1; SMN2 (0.46) USP2SMN1; SMN2CYP1A2MAPK1EPHX2
SCHEMBL30429753 0.85 USP2 (0.39) USP2SMN1; SMN2CYP1A2MAPK1CCKBR
SCHEMBL26101415 0.85 USP2 (0.39) USP2SMN1; SMN2CYP1A2MAPK1CCKBR
SCHEMBL26133816 0.81 EPHX2 (0.41) USP2SMN1; SMN2CYP1A2CCKBRSCN5A
SCHEMBL30429485 0.81 EPHX2 (0.41) USP2SMN1; SMN2CYP1A2CCKBRSCN5A
SCHEMBL26103351 0.80 L3MBTL3 (0.47) SMN1; SMN2FASNMBTD1L3MBTL3L3MBTL1
SCHEMBL30429955 0.78 FASN (0.40) EPHX2FASN
SCHEMBL26102634 0.78 FASN (0.40) EPHX2FASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333405-A1 ANTAGONISTS OF GPR39 PROTEIN VASOCARDEA INC (US) 2025-10-30 US disclosed
EP-4423090-A2 ANTAGONISTS OF GPR39 PROTEIN Vasocardea, Inc. (US) 2024-09-04 EP disclosed
WO-2023076219-A2 ANTAGONISTS OF GPR39 PROTEIN VASOCARDEA, INC. (US) 2023-05-04 WO disclosed
WO-2023076219-A2 ANTAGONISTS OF GPR39 PROTEIN VASOCARDEA, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333405-A1 ANTAGONISTS OF GPR39 PROTEIN GPR39, GPR139, GPR119 USP2 2263/4885SMN1; SMN2 3253/4885CYP1A2 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.